GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Platinum Industries Ltd

Platinum Industries Q2 FY27 Consolidated Revenue up 23.3% YoY to 1,212.7 Mn

RESULTS ▼ Concern Flagged MEDIUM RISK
📅 Filed on BSE: 05 Nov 2026, 03:02 PM IST  ·  BSE ID: 67452431-6340-47e0-bb39-4e947140a63f
View Original BSE Filing (PDF)
💡
In Simple Terms
Platinum Industries released its latest financial results, showing higher sales but lower profits, while also announcing a new health product partnership and factory updates.
🤖 AI Summary
  • Consolidated Revenue from Operations for Q2 FY27 increased 23.3% YoY to 1,212.7 Mn.
  • Consolidated Profit After Tax (PAT) for Q2 FY27 decreased 30.8% YoY to 76.0 Mn.
  • Company entered an exclusive India partnership with CAREGEN, Korea, for "Korglutide" health functional food products.
  • Egypt manufacturing facility commissioning on track, with partial capacity of 30,000 MTPA by December 31, 2026.
  • Palghar, India plant's remaining commercial production started May 21, 2026, scaling total India capacity to 85,000+ TPA.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Consolidated Revenue From Operations Q2 FY27
1,212.7 Mn
23.3%
Consolidated Profit After Tax Q2 FY27
76.0 Mn
-30.8%
Consolidated EBITDA Q2 FY27
108.3 Mn
-20.3%
Consolidated EPS Q2 FY27
1.40 Rs.
-33.5%
🏢 How This Affects the Company
📈
Business Impact
The exclusive India partnership with CAREGEN for "Korglutide" expands Platinum Industries into the health and functional food finished products segment, diversifying its business beyond existing core areas. Expansion of Egypt and Palghar plants is targeted to enhance global footprint and domestic capacity, supporting growth in non-lead additives, CPVC, and other products.
💰
Financial Impact
While Q2 FY27 consolidated revenue grew, consolidated EBITDA and PAT declined by 20.3% and 30.8% YoY respectively. Increased depreciation by 55.3% YoY for Q2 FY27 impacts profitability. The new business segment and plant expansions may require capital investment, but also aim to improve future margin profiles and operating leverage.
⚙️
Operational Impact
Partial commercial operations for CPVC at the Palghar facility commenced in Q1 FY26 and remaining operations on May 21, 2026. The Egypt plant is expected to commence partial capacity by December 31, 2026, with remaining capacity by March 31, 2027, significantly increasing manufacturing capacity to 60,000 MTPA.
⚠️
Risk Impact
The previous modified audit opinion on Q2 FY27 results and FY26 due to the Rs. 98.19 million insurance claim uncertainty persists. Significant capital expenditure for plant expansions introduces execution risks, though the company highlights de-risked economics for the Egypt plant.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this investor presentation.
👤
Who Is Affected
All shareholders are affected by the company's financial performance and strategic announcements regarding new business segments and manufacturing capacity additions.
🔍
Management Signal
Management intends to drive growth through both organic capacity expansion in core businesses and inorganic diversification into new product segments like health functional foods.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — monitor for improvement in profitability metrics.
Egypt plant commissioning — track progress on achieving partial capacity by December 31, 2026.
"Korglutide" product launch — observe market entry and revenue contribution from new segment.
MEDIUM RISK Profitability decline in Q2 FY27, coupled with prior auditor's modified opinion on results, indicate financial risks.
💡 Investor Takeaway
Platinum Industries reported Q2 FY27 consolidated revenue growth of 23.3% YoY to 1,212.7 Mn, alongside a 30.8% YoY decrease in consolidated PAT to 76.0 Mn. Key developments include a new exclusive health product partnership and updates on Palghar and Egypt plant capacity expansions.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Revenue from Operations increased 23.3% YoY in Q2 FY27 to 1,212.7 Mn, demonstrating sales growth.
  • Strategic expansion into Health & Functional Finished Product segment via exclusive India partnership for "Korglutide" provides diversification.

⚠️ Concerns

  • Consolidated Profit After Tax (PAT) decreased by 30.8% YoY to 76.0 Mn in Q2 FY27, indicating a significant drop in profitability.
  • Consolidated EBITDA Margin declined to 8.9% in Q2 FY27 from 13.8% in Q2 FY26, signaling margin pressure.
📅 Company Track Record
Platinum Industries' FY26 consolidated revenue grew 14.8% to INR 4,504.4 million, with the company targeting 35% CAGR by FY29. Auditors issued a modified opinion on FY26 and Q2 FY27 results over a Rs. 98.19 million insurance claim uncertainty.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Platinum Industries' Consolidated Revenue from Operations in Q2 FY27?
Platinum Industries reported Consolidated Revenue from Operations of 1,212.7 Mn in Q2 FY27, representing a 23.3% increase compared to Q2 FY26.
What was Platinum Industries' Consolidated Profit After Tax (PAT) in Q2 FY27?
The Consolidated Profit After Tax (PAT) for Platinum Industries in Q2 FY27 was 76.0 Mn, which is a decrease of 30.8% from Q2 FY26.
What new business segment is Platinum Industries entering?
Platinum Industries, through its wholly-owned subsidiary Rivadu Lifesciences Private Limited, has entered into an exclusive India partnership with CAREGEN, Korea, for health functional food finished products under the brand "Korglutide".
What is the update on Platinum Industries' Egypt plant expansion?
The Egypt manufacturing facility is on track to commence partial commercial operations of 30,000 MTPA by December 31, 2026, with the remaining capacity by March 31, 2027, eventually reaching 60,000 MTPA.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.